- Home
- BTAI vs KYNB Comparison
BTAI vs KYNB Comparison
Compare BTAI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | KYNB |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 31.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTAI | KYNB |
|---|---|---|
| Price | $1.24 | $7.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 29.0K |
| Earning Date | 03-27-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $141.28 | N/A |
| Revenue Next Year | $1,921.56 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $6.32 |
| 52 Week High | $8.08 | $9.58 |
Technical Indicators
Market Signals| Indicator | BTAI | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 54.04 |
| Support Level | N/A | $6.68 |
| Resistance Level | $1.77 | $7.58 |
| Average True Range (ATR) | 0.12 | 0.40 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 15.83 | 86.55 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.